- Home
- USAU vs SABS Comparison
USAU vs SABS Comparison
Compare USAU & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | SABS |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | 86 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.4M | 263.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | USAU | SABS |
|---|---|---|
| Price | $12.97 | $3.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $22.83 | $10.75 |
| AVG Volume (30 Days) | 222.2K | ★ 503.7K |
| Earning Date | 03-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,402,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.32 | $1.85 |
| 52 Week High | $23.72 | $5.15 |
Technical Indicators
Market Signals| Indicator | USAU | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 37.56 | 42.12 |
| Support Level | N/A | $3.42 |
| Resistance Level | $16.50 | $4.10 |
| Average True Range (ATR) | 0.70 | 0.16 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 23.92 | 28.24 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.